BEBT-720 leverages dual siRNA technology to target CIDEB and HSD17B13, introducing a multi-mechanism strategy for liver disease treatment. CIDEB plays a critical role in lipid droplet formation and metabolism, while HSD17B13 is associated with steroid metabolism and has protective effects against liver disease. By simultaneously silencing both genes, BEBT-720 addresses key drivers of liver pathology. Preclinical in vitro and in vivo studies demonstrate that BEBT-720 significantly reduces CIDEB and HSD17B13 expression, leading to a marked decrease in lipid droplet accumulation and liver fibrosis in MASH mouse models. These findings underscore the potential of BEBT-720 to mitigate liver damage and enhance overall liver health.